My research is focused on several basic science and translational research projects that are highly relevant to clinical diseases and pancreatic cancer. I have a strong background and research experience in organic chemistry, medicinal and synthetic chemistry, and biochemistry, including enzyme activities and mechanisms.

In recent years, I have been studying the fields of translational medicine and medicinal chemistry, working with cell-free, well-established in vitro as well as in vivo models. The primary goal of my projects is to develop new, safe, and effective therapies using natural or naturally-derived substances. For example, I have been developing medicines for hyperuricemia-related diseases, such as gout, using natural substances and by modifying their structure to enhance their effects. Currently, I am also screening naturally-derived substances for inhibitors of enzymes such as myeloperoxidase, HIV protease, and arginase, key enzymes in the development of diseases.

Another focus of my research is the delivery of nanoparticle gene/drug complexes targeted to cancer cells as well as to vascular cells by using antibodies or other specific proteins conjugated to PLGA (poly(lactic-co-glycolic acid)-based nanoparticles. I am developing a new PLGA-based material for molecular imaging and specific drug and gene delivery, which has great potential clinical applications such as molecular diagnostics and targeted therapies.